GlassScriptPhysician profile
Conrad J Rios
NPI 1326037771
$8,974.08
in general payments reported to CMS, 2019-2025
35 companies · $4,101 in 2025
The $4,101 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $302 · 2022: $598 · 2023: $1,746 · 2024: $2,228 · 2025: $4,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,075.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $996.79 | 2022-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $958.16 | 2023-2025 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals LP | $894.85 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Phathom Pharmaceuticals, INC. | $624.96 | 2024-2025 | Voquezna |
| Amgen INC. | $500.89 | 2024-2025 | Repatha, Evenity, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $409.39 | 2022-2024 | Relistor, Xifaxan |
| Ardelyx, INC. | $395.75 | 2023-2025 | Ibsrela |
| Abbvie INC. | $390.02 | 2023-2025 | |
| Madrigal Pharmaceuticals | $269.48 | 2024-2025 | Rezdiffra |
| Gilead Sciences, INC. | $250.35 | 2022-2025 | Yeztugo |
| Medtronic, INC. | $236.35 | 2022-2023 | Minimed 770g |
| Intercept Pharmaceuticals, INC. | $231.34 | 2021-2023 | Ocaliva |
| Bayer Healthcare Pharmaceuticals INC. | $225.04 | 2023-2024 | |
| Axsome Therapeutics, INC. | $223.93 | 2025 | Auvelity |
| Corcept Therapeutics | $211.90 | 2025 | Korlym |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $150.00 | 2025 | Onpattro |
| Ipsen Biopharmaceuticals, INC | $146.20 | 2024 | Iqirvo |
| Neurocrine Biosciences, INC. | $140.00 | 2023 | Ingrezza |
| Agios Pharmaceuticals, INC. | $137.39 | 2024 | Pyrukynd |
| Braeburn INC. | $125.54 | 2025 | Brixadi |
| Organogenesis INC. | $125.03 | 2024 | Puraply Wound Matrix |
| Kowa Pharmaceuticals America, INC. | $125.00 | 2025 | Zoryve |
| Eisai INC. | $125.00 | 2025 | |
| Biotronik Nro, INC. | $124.99 | 2024 | Prospera |
| Argenx US, INC. | $124.99 | 2025 | Vyvgart |
| Aimmune Therapeutics, INC. | $123.63 | 2024 | |
| Ironwood Pharmaceuticals, INC | $122.70 | 2024 | |
| Lilly USA, LLC | $121.93 | 2025 | |
| Dexcom, INC. | $116.67 | 2023 | Dexcom G7 Gss (161) |
| Biohaven Pharmaceuticals, INC. | $108.77 | 2021 | |
| Springworks Therapeutics, INC. | $94.98 | 2025 | Gomekli |
| Genentech USA, INC. | $49.74 | 2021 | |
| Glaxosmithkline, LLC. | $35.75 | 2023-2024 | Trelegy Ellipta |
| Exact Sciences Corporation | $28.89 | 2025 | The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $27.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Conrad Rios listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.